Empagliflozin/linagliptin/metformin
| Combination of | |
|---|---|
| Empagliflozin | SGLT2 inhibitor |
| Linagliptin | DPP-4 inhibitor |
| Metformin | Anti-diabetic biguanide |
| Clinical data | |
| Trade names | Trijardy XR |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Empagliflozin/linagliptin/metformin, sold under the brand name Trijardy XR, is a drug combination used for the treatment of type 2 diabetes.[2] It is a combination of empagliflozin, linagliptin, and metformin. Empagliflozin/linagliptin/metformin was approved for use in the United States in January 2020.[3][4]
Adverse effects
To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Empagliflozin should each be stopped at least three days before scheduled surgery.[5]
Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.[5]
History
The combination preparation was developed and marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.[6][7]
References
- ^ "Trijardy XR- empagliflozin, linagliptin, metformin hydrochloride tablet, extended release". DailyMed. Retrieved 24 December 2021.
- ^ Kim ES, Deeks ED (September 2015). "Empagliflozin/Linagliptin: A Review in Type 2 Diabetes". Drugs. 75 (13): 1547–57. doi:10.1007/s40265-015-0457-z. PMID 26323340. S2CID 27675087.
- ^ "Trijardy XR: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 11 February 2020.
- ^ "US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes" (Press release). Eli Lilly and Company. 27 January 2020. Retrieved 10 February 2020 – via PR Newswire.
- ^ a b "FDA revises labels of SGLT2 inhibitors for diabetes to include warning". U.S. Food and Drug Administration. 19 March 2020. Retrieved 6 June 2020.
This article incorporates text from this source, which is in the public domain.
- ^ "US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes" (Press release). Boehringer Ingelheim. 27 January 2020. Retrieved 10 February 2020.
- ^ "Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use" (PDF). Boehringer Ingelheim. Retrieved 10 February 2020.
External links
- "Empagliflozin mixture with Linagliptin". Drug Information Portal. U.S. National Library of Medicine.
- "Empagliflozin mixture with metformin hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
- "Empagliflozin". MedlinePlus.
- "Linagliptin". MedlinePlus.
- "Metformin". MedlinePlus.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- Source attribution
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from February 2020
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Alkyne derivatives
- Drugs developed by Boehringer Ingelheim
- Combination diabetes drugs
- Dipeptidyl peptidase-4 inhibitors
- Drugs developed by Eli Lilly and Company
- SGLT2 inhibitors
- All stub articles
- Gastrointestinal system drug stubs